Evolus (EOLS) Income towards Parent Company (2017 - 2026)
Evolus (EOLS) posted Income towards Parent Company of -$10.7 million for Q1 2026, down 8310.77% on a QoQ basis from $130000.0 in Q4 2025, and up 43.5% year-over-year from -$7.4 million in Q1 2025.
Evolus (EOLS) Income towards Parent Company (2017 - 2026) Analysis & Trends
Evolus' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$10.7 million for Q1 2026.
- Quarterly Income towards Parent Company rose 43.5% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.4 million (up 22.74% YoY) and the FY2025 annual result came in at -$51.6 million, down 2.42% from the prior year.
- Income towards Parent Company was -$10.7 million for Q1 2026 at Evolus, down from $130000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $130000.0 in Q4 2025 and bottomed at -$23.5 million in Q2 2022.
- A 5-year average of -$14.6 million and a median of -$15.7 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 373.41% — and 2025, when it soared 101.91%.
- Evolus' Income towards Parent Company stood at -$13.2 million in 2022, then advanced by 10.13% to -$11.8 million in 2023, then soared by 42.6% to -$6.8 million in 2024, then jumped by 101.91% to $130000.0 in 2025, then plunged by 8310.77% to -$10.7 million in 2026.
- Business Quant data shows EOLS's Income towards Parent Company at -$10.7 million in Q1 2026, $130000.0 in Q4 2025, and -$15.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |
| Jun 30, 2021 | -15.60 Mn |